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olites of the mevalonate pathway which trigger proliferation of a
subset of cytotoxic gamma, delta T cells and cytokine release.
Several studies are now in progress investigating whether this
immunomodulatory effect of zoledronic acid can be utilized in
oncology to enhance its therapeutic potential beyond the well
established inhibition of tumour-induced osteolysis.
doi:10.1016/j.ejcsup.2006.04.047
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Background: Non small cell lung cancer (NSCLC) is the leading
cause of cancer related deaths, mostly secondary to diffuse extra-
thoracic spread of the disease in several organs and systems. Bone
metastases (BM) may be present at diagnosis or develop in the fol-
low up, are associated with a worse prognosis, and currently there
are no chemical or biological markers predicting their clinical
onset. Several molecules are potential factors favouring bone dis-
semination by cancer cells, including cell cycle proteins, angioge-
netic factors, extra-cellular matrix proteins and their inhibitors,
serum and plasma proteins implicated in bone resorption mecha-
nisms. Increased levels of some of these molecules (periostin, BSP
and osteopontin) were found in colon, breast and prostate can-
cers. Their role in lung cancer is controversial. Aim of this study
was to investigate the predictive and prognostic value of bone
resorption-related molecules in favouring or modulating the colo-
nisation of bone tissue during haematogenous spread of NSCLC.
Methods: Thirty cases of resected NSCLC which developed BM
(group A – mean follow up time 27.2 months) were matched for
several clinico-pathological parameters (including age, sex, stage
of the disease, histology, differentiation grade, adjuvant therapy)
to 30 cases of resected NSCLC without any metastases (group B –
mean follow up time 75.1 months) and 26 resected NSCLC with
non-bone metastases (group C – mean follow up 21.1 months).
Primary tumor samples were investigated by a standard auto-
mated immunoperoxidase procedure for 10 markers previously
recognized to be involved in bone resorption or metastatization
process (cathepsin K, bone sialoprotein [BSP],VEGF, MMP-2, p53,
RECK, TIMP-1, CD-117, Ki-67 and TRAcP). For statistical analysis,
the staining distribution in tumor cells was assessed by a semi-
quantitative score (0, <10%, 10–50%, >50% positive tumor cells).
Differences among groups were estimated by v2 test, whereas
the prognostic impact of clinico-pathological parameters and
marker expression was evaluated by univariate and multivariate
analyses. An additional series of 120 resected consecutive NSCLC
was also tested for BSP expression prevalence (group D).
Results: Among the different markers investigated, BSP expres-
sion was significantly higher in bone metastatic cases (80%)
compared to 20% and 31% of groups B (non metastatic) and C
(non-bone metastases), respectively (p < 0.001). BSP expression
did not show any difference according to tumor histotype or
any other characteristics. In addition, taking all the three groups
together, or the metastatic groups (groups A and C) alone, BSP
expression was also shown to be related to poor outcome
(p = 0.02 by Mantel–Cox test). None of the other markers was dif-
ferentially expressed within the groups or demonstrated a prog-
nostic impact, both in terms of overall survival and of time
interval to metastases. BSP was further estimated in 120 resected
NSCLCs (M:F ratio 3:1; mean age 67 years; histotype: adenocarci-
nomas 55%, squamous cell carcinoma 39%, others 6%; stages: I
54%, II 17%, III 29%) and a prevalence of 40% observed, without
any statistically significant difference according to histotype or
other clinico-pathological parameters.
Discussion: In this study, we have shown that BSP is signifi-
cantly more expressed in a series of NSCLC metastatic to bone
as compared with matched control groups of NSCLC (metastatic
or non metastatic) which did not progress to bone in the same
period of time. BSP expression was also found to be predictive
of poor prognosis, but not related to the time interval to distant
spread. Moreover, in a large consecutive series of resected NSCLC
we observed a prevalence of BSP protein expression of 40%. Inter-
estingly, this percentage of positivity is intermediate between
that in group A on the one side, and groups B and C on the other.
The biological significance of BSP expression in tumors progress-
ing to bone metastases is not fully understood. The balance of
bone apposition and resorption involves several molecules,
locally produced or possibly blood-born, which act through differ-
ent specific circuits. BSP itself may be powering the effect of bone
resorption and facilitate bone colonisation by tumor cells. In
in vitro models, BSP favoured cancer cell invasiveness through a
linkage with integrins and MMP2. Inhibition of BSP-MMP2 com-
plex was able to block BSP-enhanced invasiveness. Our findings
suggest that in the future NSCLC patients with BSP expression,
may benefit of BSP inhibitors and may also be reasonably good
candidates for preventive treatments (i.e., bone metabolic agents)
in order to block, reduce or delay the osteotropism of cancer cells.
In conclusion, immunohistochemical expression of BSP in resected
NSCLC strongly predicts bone dissemination, and may therefore
be useful in selecting patients for treatments targeted to contrast
bone metastatic spread.
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CD133 positive ‘‘Cancer Stem Cells’’ (CSC) have been shown to ini-
tiate and maintain glioblastoma growth. The first aim of our stud-
ies was to further characterize CD133+ cells in gliomas of different
grades with respect to their prospective origin and differentiation
potential. CD133+ cells could be identified in gliomas grade II–IV.
Co-expression of CD133 and Musashi-1 indicated a neural stem
cell character of CD133+ cells. Expression of both markers was
clearly grade dependent with up to 20% of cells being CD133+ in
GBM. Under different culture conditions, CD133+ cells isolated
from gliomas lost CD133 expression and started expression of
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